---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-119946"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-11-20T23:59:59+00:00"
generated_at: "2026-06-07T23:12:32.365913+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics terminates Interim CFO; CEO assumes principal financial officer role

## Summary
- On Nov 17, 2023, Marker terminated Danforth Advisors consulting agreement, effective Jan 16, 2024.
- Eliot M. Lurier ceased as Interim CFO and Principal Financial and Accounting Officer immediately.
- CEO Juan Vera appointed as Principal Financial and Accounting Officer effective Nov 17, 2023.
- No replacement CFO has been announced; CEO will handle financial officer duties.

## SEC filing metadata
- accession: 0001104659-23-119946
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-11-20T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923119946/0001104659-23-119946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923119946/tm2330976d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-119946
- JSON: https://secwatch.observer/filing/0001104659-23-119946.json
- Plain text: https://secwatch.observer/filing/0001104659-23-119946.txt

## Key facts
- Executive change
  Eliot M. Lurier departed as Interim Chief Financial Officer and Principal Financial and Accounting Officer at Marker Therapeutics, Inc..
  - Action: ceased serving
  - Role: Interim Chief Financial Officer and Principal Financial and Accounting Officer
  source text: On November 17, 2023, Mr. Lurier ceased serving as the Company’s Interim Chief Financial Officer and Principal Financial and Accounting Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465923119946/0001104659-23-119946-index.htm
- Executive change
  Juan Vera was appointed as Principal Financial and Accounting Officer at Marker Therapeutics, Inc..
  - Action: appointed
  - Role: Principal Financial and Accounting Officer
  source text: Juan Vera, the Company’s President and Chief Executive Officer, was appointed as the Company’s Principal Financial and Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465923119946/0001104659-23-119946-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.